My small effort to present an article with PPT presentation for learning purpose.
Color codes in the article PDF document:
1) Green for positive criticism
2) Red for negative criticism
3) Yellow for important points
3)
What is the correlation between CNS active medication and fall risk for the geriatric community and how should one best prevent fall injuries from occurring for those taking such medication?
Personalised Medicine is a young but rapidly advancing field.
The term 'Personalised Medicine' is described as providing "the right patient with the right drug at the right dose at the right time".
What is the correlation between CNS active medication and fall risk for the geriatric community and how should one best prevent fall injuries from occurring for those taking such medication?
Personalised Medicine is a young but rapidly advancing field.
The term 'Personalised Medicine' is described as providing "the right patient with the right drug at the right dose at the right time".
Syringe driver medications: A study of combinations and clinical stability
Derryn Gargiulo, Jeff Harriso, Emma Griffiths, Bruce Foggo, Lauren Doherty, Sana Khan, Kate Kilpatrick, Guangda Ma, Caitlin Renouf, Susan Wilson
Estimating the Maximum Safe Starting Dose for First-in-Human Clinical TrialsMaRS Discovery District
Part of the MaRS BioEntrepreneurship series session: Clinical Trials Strategy
Speaker: Beatrice Setnik
This is available as an audio presentation:
http://www.marsdd.com/bioent/feb12
Also view the event blog and summary:
http://blog.marsdd.com/2007/02/14/bioentrepreneurship-clinical-trial-strategies-its-never-too-soon/
Oliver Howes - Treatment-Resistant Schizophrenia: New Guidelines on Diagnosis...wef
Presentation made at the live webinar hosted by the Schizophrenia Research Forum on the 21st of February, 2017 - http://www.schizophreniaforum.org/forums/treatment-resistant-schizophrenia-new-guidelines-diagnosis-and-terminology
Alex's Lemonade Stand Foundation holds an annual Childhood Cancer Symposium in Philadelphia. It is designed to be an educational resource, providing families with the opportunity to learn about issues and topics of treatment and beyond, while meeting other families in a group setting. Registration is free and is open to all those touched by childhood cancer, including patients and their siblings.
Hear from speaker Rochelle Bagatell, MD of Children's Hospital of Philadelphia as she discusses clinical trials and experimental treatments in childhood cancer cases.
For more information on Alex's Lemonade Stand Foundation's childhood cancer resources, click here: http://www.AlexsLemonade.org
PyratineXR®- Lotion for Improving the Signs and Symptoms of RosaceaFrank J. Massino
This in-depth article highlights the results of an open-label study testing the efficacy and tolerability of PRK 124 (0.125%), the active ingredient in PyratineXR®, in treating mild to moderate rosacea.
A Bifactor and Itam Response Theory Analysis of the Eating Disorder Inventory-3David Garner
The Eating Disorder Inventory-3 (EDI-3; Garner, 2004) is a 91-item, self-report measure scored on 12 scales (three Eating
Disorder Risk scales, nine Psychological scales) and six composites. A sample of 1206 female eating disorder patients was
divided randomly into calibration (n = 607) and cross-validation (n = 599) samples for confirmatory factor analyses. A bifactor
model best fit the data in both samples, but a model with second-order factors corresponding to the risk and psychological scales
approached the fit of the bifactor model.
Evaluation of cutaneous adverse drug reactions due to antimicrobial agents: A...iosrjce
IOSR Journal of Dental and Medical Sciences is one of the speciality Journal in Dental Science and Medical Science published by International Organization of Scientific Research (IOSR). The Journal publishes papers of the highest scientific merit and widest possible scope work in all areas related to medical and dental science. The Journal welcome review articles, leading medical and clinical research articles, technical notes, case reports and others.
Clinical trial of homeopathy in rheumatoid arthritishome
The conclusion of the study that the effect was due to
‘consultation’ and not to the homeopathic remedy appears
to be biased for two reasons:
There was no substantial amelioration of the pathology
in any group to compare and on which to base conclusions.
The placebo effect in such deep pathology cases is superficial
and transient as the patient remains in essence with
the same frame of pathology.
Syringe driver medications: A study of combinations and clinical stability
Derryn Gargiulo, Jeff Harriso, Emma Griffiths, Bruce Foggo, Lauren Doherty, Sana Khan, Kate Kilpatrick, Guangda Ma, Caitlin Renouf, Susan Wilson
Estimating the Maximum Safe Starting Dose for First-in-Human Clinical TrialsMaRS Discovery District
Part of the MaRS BioEntrepreneurship series session: Clinical Trials Strategy
Speaker: Beatrice Setnik
This is available as an audio presentation:
http://www.marsdd.com/bioent/feb12
Also view the event blog and summary:
http://blog.marsdd.com/2007/02/14/bioentrepreneurship-clinical-trial-strategies-its-never-too-soon/
Oliver Howes - Treatment-Resistant Schizophrenia: New Guidelines on Diagnosis...wef
Presentation made at the live webinar hosted by the Schizophrenia Research Forum on the 21st of February, 2017 - http://www.schizophreniaforum.org/forums/treatment-resistant-schizophrenia-new-guidelines-diagnosis-and-terminology
Alex's Lemonade Stand Foundation holds an annual Childhood Cancer Symposium in Philadelphia. It is designed to be an educational resource, providing families with the opportunity to learn about issues and topics of treatment and beyond, while meeting other families in a group setting. Registration is free and is open to all those touched by childhood cancer, including patients and their siblings.
Hear from speaker Rochelle Bagatell, MD of Children's Hospital of Philadelphia as she discusses clinical trials and experimental treatments in childhood cancer cases.
For more information on Alex's Lemonade Stand Foundation's childhood cancer resources, click here: http://www.AlexsLemonade.org
PyratineXR®- Lotion for Improving the Signs and Symptoms of RosaceaFrank J. Massino
This in-depth article highlights the results of an open-label study testing the efficacy and tolerability of PRK 124 (0.125%), the active ingredient in PyratineXR®, in treating mild to moderate rosacea.
A Bifactor and Itam Response Theory Analysis of the Eating Disorder Inventory-3David Garner
The Eating Disorder Inventory-3 (EDI-3; Garner, 2004) is a 91-item, self-report measure scored on 12 scales (three Eating
Disorder Risk scales, nine Psychological scales) and six composites. A sample of 1206 female eating disorder patients was
divided randomly into calibration (n = 607) and cross-validation (n = 599) samples for confirmatory factor analyses. A bifactor
model best fit the data in both samples, but a model with second-order factors corresponding to the risk and psychological scales
approached the fit of the bifactor model.
Evaluation of cutaneous adverse drug reactions due to antimicrobial agents: A...iosrjce
IOSR Journal of Dental and Medical Sciences is one of the speciality Journal in Dental Science and Medical Science published by International Organization of Scientific Research (IOSR). The Journal publishes papers of the highest scientific merit and widest possible scope work in all areas related to medical and dental science. The Journal welcome review articles, leading medical and clinical research articles, technical notes, case reports and others.
Clinical trial of homeopathy in rheumatoid arthritishome
The conclusion of the study that the effect was due to
‘consultation’ and not to the homeopathic remedy appears
to be biased for two reasons:
There was no substantial amelioration of the pathology
in any group to compare and on which to base conclusions.
The placebo effect in such deep pathology cases is superficial
and transient as the patient remains in essence with
the same frame of pathology.
Identifying Significant Antipsychotic-Related Side Effects in Patients on a Community Psychiatric Rehabilitation Unit-A Feasibility Study of The Glasgow Antipsychotic Side-Effect Scale (GASS) by Ahmed Saeed Yahya* in crimson publishers: Journal of Physical Medicine and Rehabilitation
Antipsychotic side-effects are common and are an important determinant of non-adherence and consequent relapse. Most rating scales for the identification of these are lengthy and complicated. This report reviews the medical literature on the Glasgow antipsychotic side-effect scale (GASS)-a brief and validated rating scale to measure the unwanted effects of antipsychotics. We administered the GASS to fourteen in-patients in a United Kingdom-based Community Psychiatric Rehabilitation Unit. The objective was to establish the utility of the GASS in this setting and to make recommendations on how this tool could be used in clinical practice to improve adherence to antipsychotic medication.
https://crimsonpublishers.com/epmr/fulltext/EPMR.000529.php
For more Open access journals in Crimson Publishers
Please click on: https://crimsonpublishers.com/
For more articles in Examines in Physical Medicine & Rehabilitation
Please click on: https://crimsonpublishers.com/epmr/
A very comprehensive, crisp, lucid presentation introducing the basics of Clinical research.
Globally recognized scientists:
1) Louis Pateur:
a. French chemist and microbiologist
b. principles of vaccination, microbial fermentation, and EPONYMOUS process of Pasteurization
c. Integral Part of our everyday life
d. germ theory of disease
e. cure for anthrax, rabies
2) Charles Darwin
a. Angry with his father Bent on proving our forefathers were monkeys
b. Descent of Man
c. Natural selection
d. Evolution
Slide 5
1. FINER criteria for research topic:
a. Feasible
b. Interesting
c. Novel does not necessarily mean that the research has not been done before. The prefix “re” in the word research implies searching again add to the existing body of knowledge
d. Ethical justification
e. Relevant
Slide 6
3) History:
a. Book of Daniel
b. King Neba-ka-nezzar
c. Wine & meat
d. Daniel & 3 fellows Legume + water diet x 10 days
4) Avicenna (10th AD)
5) Concept paper 1 paper document
Slide 9
1. Cohort Prospective, retrospective
SMART criteria:
a. Specific b. Measurable c. Achievable d. Realistic e. Time-bound
Slide 12
1. What to do: Hypothesis generation
2. Why did I begin: Intro
3. What did I do Methodology
4. What did I find: Results
5. What it means Discussion
b. Abbreviations:
a. IP- Investigational Product
Comprehensive, concise and full proof way of receiving grants to fund a research study with salient components listed below.
Covering letter: Letter to funding agencies enlisting all enclosures
1. Title page (PICOT) – upto 25 words
2. Abstract (IMRaD format) without
a. Results
b. Conclusion
3. Introduction: (FINER) upto 300 words
a. Problem statement
b. Knowledge gaps in existing scientific literature
c. Novelty
d. Societal impact
e. End with hypothesis & (SMART) Objectives: 100 words
i. Preferably 2: 1 primary and 1 or 2 secondary
4. Literature review
5. MethodologyProject Description 800 words
a. Detailed Study design, population, Sampling procedure with sample size determination, Data collection procedures, Statistics, Ethical considerations
b. Seamless connection between sections
c. Administrative part in order Institutional permissions, Bank details
6. Budget & Justification: 100 words
a. Recurring
a. Stationary
b. Equipment maintenance
b. Non-recurring
a. IEC fees
b. Bank processing charges
c. Research team Research coordinator, research assistant, research associate
7. Timeline: Gantt chart
8. References: Upto 5 upto 300 words
a. Vancouver style
b. APA
This presentation was delivered at a national conference EBCCON2023, SRM medical college, Chennai. The presentation was timed for eight minutes with two minutes of discussion. It describes evaluation of potential analgesic effect of Vitamin D3 in comparison to tramadol and diclofenac using hot plate test and acetic acid induced writhing test. Prior institutes ethics committee permission was taken and CPCSEA guidelines were followed. The study was conducted over a period of 63 days following principle of 5Rs of animal experiment. Animals were reused for two different models.
This presentation with the above title was presented by me as a part of training programme for superspecialty course DM Clinical Pharmacology in Seth GSMC and Kem hospital, Mumbai as a short seminar. Find this for unlimited sharing and may this be of use to all.
A short presentation covering salient features of pathophysiology, diagnosis, clinical pharmacology of management of osteoporosis. Covers in short diagnostics, most of the drugs used in osteoporosis management, with Denosumab example with a clinical trial covered as example. This presentation serves as a model answer to prepare for pharmacology exam questions.
Clinical Pharmacology of Pulmonary arterial hypertension with Recent advances. Discusses pathobiology, symptomatology, diagnostics and pharmacotherapy of PAH
Brief 10 minute presentation about certain challenges which Clinical pharmacologist come across while conducting Clinical Trials on phytopharmaceuticals. Not comprehensive but will entice your think tank.
The presentation is a brief overview of issues Clinical Pharmacologists and team come across during various processes involved in conduct of clinical trial of infectious diseases. It also discusses off-track topics but related topics like Antimicrobial Stewardship and ends with measures suggested to overcome some of the challenges.
CREATED with the intention to spread awareness in language masses can easily understand. Intended for Hindi/English speaking population.
Basic knowledge about Sars-Cov-2, NCovid19 and management.
A brief overview of Challenges in conducting Trial of medical devices. My small endeavor in understanding #clinicalTrials of MDs. Includes Medical Device rule 2017 too.
This was my first podium presentation presented at an international conference organized by UNESCO. The conference was remarkable because it involved superspecialty field to even nursing staff. My presentation was amongst the contenders for prize distribution. However, it did not happen so due to other presenters who outperformed me.
A brief presentation about the abovementioned title, it covers historical aspects, about the process of therapeutic drug monitoring, its indications, criteria, team involved and so on and so forth.
This particular presentation of mine covers salient features of recent drug developed for treatment of dyslipidaemia particularly familial hypercholesterolemia. This presentation also covers recent modifications in treatment guidelines.
An academic presentation on General Anesthetics, covering only the Pharmacological aspect of the drugs (ie the Pharmacokinetic and pharmacodynamic profile) available for general anesthesia. Topics not covered are different mechanisms of administering anesthesia and other basics of anesthesia.
More from Seth GSMC and KEM Municipal Hospital (20)
Acetabularia Information For Class 9 .docxvaibhavrinwa19
Acetabularia acetabulum is a single-celled green alga that in its vegetative state is morphologically differentiated into a basal rhizoid and an axially elongated stalk, which bears whorls of branching hairs. The single diploid nucleus resides in the rhizoid.
Model Attribute Check Company Auto PropertyCeline George
In Odoo, the multi-company feature allows you to manage multiple companies within a single Odoo database instance. Each company can have its own configurations while still sharing common resources such as products, customers, and suppliers.
Macroeconomics- Movie Location
This will be used as part of your Personal Professional Portfolio once graded.
Objective:
Prepare a presentation or a paper using research, basic comparative analysis, data organization and application of economic information. You will make an informed assessment of an economic climate outside of the United States to accomplish an entertainment industry objective.
The French Revolution, which began in 1789, was a period of radical social and political upheaval in France. It marked the decline of absolute monarchies, the rise of secular and democratic republics, and the eventual rise of Napoleon Bonaparte. This revolutionary period is crucial in understanding the transition from feudalism to modernity in Europe.
For more information, visit-www.vavaclasses.com
Honest Reviews of Tim Han LMA Course Program.pptxtimhan337
Personal development courses are widely available today, with each one promising life-changing outcomes. Tim Han’s Life Mastery Achievers (LMA) Course has drawn a lot of interest. In addition to offering my frank assessment of Success Insider’s LMA Course, this piece examines the course’s effects via a variety of Tim Han LMA course reviews and Success Insider comments.
Synthetic Fiber Construction in lab .pptxPavel ( NSTU)
Synthetic fiber production is a fascinating and complex field that blends chemistry, engineering, and environmental science. By understanding these aspects, students can gain a comprehensive view of synthetic fiber production, its impact on society and the environment, and the potential for future innovations. Synthetic fibers play a crucial role in modern society, impacting various aspects of daily life, industry, and the environment. ynthetic fibers are integral to modern life, offering a range of benefits from cost-effectiveness and versatility to innovative applications and performance characteristics. While they pose environmental challenges, ongoing research and development aim to create more sustainable and eco-friendly alternatives. Understanding the importance of synthetic fibers helps in appreciating their role in the economy, industry, and daily life, while also emphasizing the need for sustainable practices and innovation.
Embracing GenAI - A Strategic ImperativePeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
Biological screening of herbal drugs: Introduction and Need for
Phyto-Pharmacological Screening, New Strategies for evaluating
Natural Products, In vitro evaluation techniques for Antioxidants, Antimicrobial and Anticancer drugs. In vivo evaluation techniques
for Anti-inflammatory, Antiulcer, Anticancer, Wound healing, Antidiabetic, Hepatoprotective, Cardio protective, Diuretics and
Antifertility, Toxicity studies as per OECD guidelines
How libraries can support authors with open access requirements for UKRI fund...
For slideshare How to Critically-Appraise a Journal Article
1. Critical Appraisal of A Journal
Article
Dr. Shakeeb Dhorajiwala,
MBBS, MD. Pharmacology, DM 1st year resident- Department Of Clinical Pharmacology
Former Scientist B in project “Covishield”,
Presentation for: Dept. of Clinical Pharmacology, Seth GSMC & KEM hospital, Parel, Mumbai.
2. Link to the article
https://s.docworkspace.com/d/AAHGiCOfprJbqaG2_OedFA
• Disclaimer: For Educational Purpose only (non-commercial use)
11-02-2021 2
3. Introduction(1/5)
Major depressive disorder widespread debilitating illness.
Prevalence: 300 million1
High rate of :
• medical,
• psychiatric co-morbidity,
• functional impairment
• Personal and societal cost
F:M= 1.5:1
Leading cause of disability in both
11-02-2021
1. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C,et al. Disability-adjusted life years (DALYs) for 291 diseases
andinjuries in 21 regions, 1990-2010: A systematic analysis for the global burden of disease study 2010. Lancet
2012;380:2197-223
3
5. Limitations of existing treatment(3/5)
TCAs SSRIs
• commonly prescribed too
• Lack of efficacy and tolerability non-
compliance
11-02-2021 5
6. Test Drug- Vilazodone(4/5)
less disruption of other neurotransmitter system.2
greater tolerability
high selectivity
high affinity for 5-HT receptor
5HT partial agonist reuptake= 5-HT reuptake inhibition + 5-HT1A partial agonism
MOA:
11-02-2021 2. Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 2003;53:193-203. 6
7. Rationale for the study(5/5)
Efficacy at 40 mg/day in MDD proved2
Nearly half of patients diagnosed with MDD anxiety problem too
Residual anxiety increased risk of MDD relapse
Also proven efficacy in GAD, MDD and MDD with anxiety
Scarcity of studies done on Indian population
No direct head-to-head comparison of efficacy and tolerability
11-02-2021
GAD: Generalized anxiety disorder
2.Croft HA, Pomara N, Gommoll C, Chen D, Nunez R, Mathews M. Efficacy and safety of vilazodone in major depressive disorder: A
randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2014;75:e1291-8.
7
8. Methodology: Study Design(1/7)
Randomized, prospective, comparative, parallel-group, open-label
Period: February 2016 - October 2017
Site: Psychiatry OPD of a tertiary care teaching hospital.
Approved by the IEC
in accordance with ICH-GCP guidelines and the ethical principles as mentioned in the DoH.
WIVC in vernacular language with detailed history and physical examinations done
11-02-2021 WIVC: written informed valid consent IEC: institutional ethics committee 8
9. Outcome Measure (2/7)
Efficacy:
• 1o : ΔHAMD-17 score from
baseline to wk 12
• >20 % improvement in first
2 weeks from baseline:
Clinically meaningful
• 2o: ΔMADRS and HAM-A
from baseline to wk 12
Safety:
• Modified Hartwig and Siegel
scale- AE severity
• Naranjo ADR Probability
Scale- Causality
11-02-2021 9
10. Cont’d(3/7)
f/u visits: 2, 4 and 12 weeks
Compliance was assessed by empty blister packets
Rescue management:
• i/c/o no response or worsening: withdrawal from study with
subsequent psychiatric care
No post-trial access
11-02-2021 10
11. Selection Criteria (4/7)
Inclusion
Newly diagnosed patients :MDD (DSM-5)
Either gender,
Aged :18 - 60 years
HAMD-17 score ≥22
Exclusion
Patients of :
• severe depression who may not respond to
pharmacotherapy
• on ECT within 3 months
• suffering from any other psychiatric disorders except
GAD;
• impaired renal/hepatic function;
• requiring other psychotropic/active medications, or
other systemic disorder;
• taken investigational drug or participated in an
investigational drug trial within past 30 days;
• Pregnant, lactating women and women of reproductive
age group
11-02-2021 HAMD-17: 17-item Hamilton Depression Rating Scale 11
13. Statistical Analysis (6/7)
sample size calculated based on change in HAMD score from baseline to week 12 and standard
deviation (SD) = 10.38 from previous studies,
α = 5% and 1-β= 80%.
required sample size : 20/ group with dropout rate of 20%,
Power and Sample Size Calculation software version 3.0.43
Categorical data: Chi-square test
11-02-2021 13
14. Statistics cont’d (7/7)
continuous variables: one-way ANOVA
1o and 2o efficacy parameters analyzed by Friedman test Dunn’s test: within-group comparison at
different follow-up visits
Kruskal–Wallis test Dunn’s test : between groups comparison.
P < 0.05 :statistically significant.
GraphPad Prism version 5.01 (GraphPad software Inc., California, USA) for analysis.
11-02-2021 14
15. Results(1/6)
N= 60 randomized and
allocated to 3 groups,
50 completed study as
per protocol
10 dropouts:
3 in amitriptyline group
(2-ADRs & 1-lack of
efficacy),
4 in escitalopram group
(1-ADRs,
1-lack of efficacy, 2 lost
to follow-up),
3 in vilazodone group (1-
ADRs and 2-lost to
follow-up).
11-02-2021 15
20. Safety evaluation (6/6)
Modified Hartwig
and Siegel scale:
for severity
assessment
Mild- level 1
Naranjo scale:
Probable
Constipation Sedation Nausea
Possible
Headache
11-02-2021 20
21. Discussion: Study findings(1/9)
11-02-2021 21
Finding no.1: significant
reduction in HAMD-17
and/or MADRS scores
compared to baseline at
4 weeks
Finding no.2: reduction in
scores at two weeks
significantly more than
amitriptyline but similar to
escitalopram.
Inference: at 2 weeks,
vilazodone more
efficacious than
amitriptyline.
Finding no.3: reduction in
HAMD-17 and MADRS
scores highest
compared to other two
groups at week 4 and
week 12,
Inference: vilazodone is
more efficacious than the
other two study drugs.
22. Cont’d (2/9)
Finding no. 4:
MADRS-sustained response
- MADRS score ≤12 for at
least the last two
consecutive visits
comparable with
escitalopram group
significantly higher than the
amitriptyline group at 12
weeks
Inference: treatment
benefits are maintained
beyond a single time point
Finding 5:
Reduction in HAM-A score
at 4th and 12 weeks
compared to baseline
Inference: beneficial effect
of vilazodone in anxiety.
11-02-2021 22
23. What other studies showed(3/9)
Vilazodone at 40 mg/day statistically significant decrease in HAMD-17 and/or MADRS scores
following 8-week treatment all placebo-controlled studies
Effects reported as early as 1 or 2 weeks
Studies supportive of sustained effect (4th finding)of vilazodone. However, effect compared only to
escitalopram.
Therapeutic effect of vilazodone in dose of 20 mg/40 mg/day in generalized anxiety disorder has
been demonstrated in double-blind, randomized, placebo-controlled clinical trials supporting 5th
finding.5
11-02-2021
5. Durgam S, Gommoll C, Forero G, Nunez R, Tang X, Mathews M, et al. Efficacy and safety of vilazodone in patients with generalized anxiety
disorder: A Randomized, double-blind, placebo-controlled, flexible-dose trial. J Clin Psychiatry 2016;77:1687-94.
23
24. Justification for Dose Selection(4/9)
studies comparing
doses of 20 mg and
40 mg/day reported-
• statistically significant beneficial effects with 20 and
40mg
• no significant differences between the different
vilazodone doses.3
• One study even reported that dose of vilazodone above
20 mg/day did not yield additional benefit.4
• one study reported better tolerability with 20 mg dose3
11-02-2021
3. Mathews M, Gommoll C, Chen D, Nunez R, Khan A. Efficacy and safety of vilazodone 20 and 40mg in major depressive disorder: A randomized,
double-blind, placebo-controlled trial. Int Clin Psychopharmacol 2015;30:67-74
4. Laughren TP, Gobburu J, Temple RJ, Unger EF, Bhattaram A, Dinh PV, et al. Vilazodone: Clinical basis for the US food and drug administration’s
24
26. Evaluation of Safety Profile (6/9)
Adverse effects with antidepressant drugs are common
negatively impact patient outcomes.
vilazodone (29.41%) and escitalopram (25%) groups comparable
amitriptyline group (52.94%) significantly higher
Intolerability to medication is one of the most common reasons of discontinuation of antidepressant
treatment.[29]
Constipation and sedation were major adverse events
11-02-2021 26
27. Cont’d (7/9)
Nausea and headache major adverse events in escitalopram and vilazodone
groups.
GI s/e of mild severity and transient.
Sexual dysfunction is a common adverse effect of SSRIs which are currently the
most commonly used antidepressants.[4]
Sexual dysfunction as a s/e reported by none.
11-02-2021 27
28. Limitations (8/9)
open-label study
small sample size restricts generalizability of study
results
Third, assessing adverse effects on sexual functions
difficult since they did not use any measurable criteria
11-02-2021 28
29. Conclusion (9/9)
Although results
of their study
show that
vilazodone is
more efficacious
antidepressant
compared to
escitalopram
and
amitriptyline:
• small sample size of this study does not allow
generalization of results
• High cost of vilazodone another hindrance
• Hence, they suggested that vilazodone be
considered as a treatment option in selected
group of MDD patients with coexisting anxiety not
responding satisfactorily to standard drugs.
• However, even this needs to be substantiated by
large-scale studies with larger sample size and
having an active comparator group.
11-02-2021 29
Editor's Notes
TCA: slow onset- upto 1 month
Only 2/3 improve and 1/3 remit